C-peptide vs Cotadutide
Head-to-head comparison of C-peptide (Connecting peptide (C-peptide)) and Cotadutide (MEDI0382, long-acting GLP-1 and glucagon receptor dual agonist) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | C-peptide | Cotadutide |
|---|---|---|
| Category | Pain Management | Weight Management |
| Full Name | Connecting peptide (C-peptide) | MEDI0382, long-acting GLP-1 and glucagon receptor dual agonist |
| Molecular Weight | 3020.3 Da | ~4,700 Da |
| Half-Life | ~20-30 min | Approximately 24 hours |
| Amino Acids | 31 | 37 |
| Typical Dose | no approved analgesic dose|research-only | 0.3-3 mg daily in clinical studies |
| Route | IV|subQ | Subcutaneous |
| Purity | ≥98% | ≥98% |
| Studies Count | 46 | 18 |
| Research Status | Pre-clinical | Clinical |
C-peptide Benefits
- ✓diabetic neuropathy research
- ✓nerve function support
- ✓possible analgesic effect
Cotadutide Benefits
- ✓body-weight reduction
- ✓improved insulin sensitivity
- ✓reduced hepatic fat
- ✓appetite suppression
C-peptide Dosing
0.5-1.0 mg/day in research|route varies by protocol
Cotadutide Dosing
Once-daily SC in trials|Start low and titrate based on tolerance|Monitor GI adverse effects
C-peptide Side Effects
- ⚠injection-site reactions
- ⚠unknown long-term safety
Cotadutide Side Effects
- ⚠nausea
- ⚠vomiting
- ⚠diarrhea
Research Overview
C-peptide
C-peptide is not an approved analgesic, but multiple studies have examined its effects on peripheral nerve blood flow and neuropathy outcomes. The strongest relevance is in diabetic neuropathic pain rather than migraine.
Cotadutide
Phase 2 studies reported dose-dependent weight loss and favorable changes in glycemic and liver-related markers. It is one of the most cited synthetic dual-agonist peptides for obesity research.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.